Physician profile
Robert G Helwig
NPI 1154321313
$1,332.91
in general payments reported to CMS, 2019-2025
21 companies · $337 in 2025
The $337 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.46 · 2020: $23.37 · 2021: $62.45 · 2022: $288 · 2023: $231 · 2024: $336 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $242.79 | 2023-2025 | Miebo, Infuse, Xiidra |
| Oyster Point Pharma, INC. | $192.17 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $162.42 | 2019-2024 | Cequa |
| Novartis Pharmaceuticals Corporation | $122.98 | 2019-2022 | |
| Dompe US, INC. | $86.92 | 2024-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $67.82 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $66.58 | 2024-2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $60.56 | 2021-2025 | Dupixent |
| Ucb, INC. | $57.47 | 2022-2024 | Bimzelx |
| Amgen INC. | $52.23 | 2024-2025 | Otezla, Tepezza |
| Alcon Vision LLC | $52.04 | 2022-2025 | Tryptyr |
| Abbvie INC. | $25.50 | 2024 | |
| Harrow Eye, LLC | $24.21 | 2024 | Vevye |
| Aerie Pharmaceuticals, INC. | $21.13 | 2021 | |
| Biotissue Holdings INC. | $18.65 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $14.39 | 2023 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.36 | 2022 | |
| Janssen Biotech, INC. | $14.35 | 2025 | Tremfya |
| Fresenius Kabi USA, LLC | $13.64 | 2023 | |
| Shire North American Group INC | $11.57 | 2019 | |
| Kala Pharmaceuticals, INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Helwig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.